2-n-Butyl-1-naphthol | 50882-61-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-n-Butyl-1-naphthol
• 英文别名: 1-Hydroxy-2-butyl-naphthalin；2-Butyl-[1]naphthol；2-Butylnaphthalen-1-ol
• CAS: 50882-61-6
• 化学式: C₁₄H₁₆O
• 分子量: 200.28
• InChiKey: VURUNMWLBDYAMB-UHFFFAOYSA-N

物化性质

• 熔点：
  71-72 °C
• 沸点：
  145-149 °C
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-n-Butyl-1-naphthol 在 15-冠醚-5 、 2-azido-1,3-dimethylimidazolinium chloride 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.0h， 以23%的产率得到2-Butyl-4-diazonionaphthalen-1-olate
  参考文献：
  名称：

  Synthesis of Diazonaphthoquinones from Naphthols by Diazo-Transfer Reaction with 2-Azido-1,3-dimethylimidazolinium Chloride

  摘要：

  描述了一种高效合成纳夫托酮二氮化物的方法。通过与由2-氯-1,3-二甲基咪唑鎓盐与叠氮化钠反应制备的2-叠氮-1,3-二甲基咪唑鎓氯化物进行二氮转移，合成了多种相应的纳夫托酮二氮化物。

  DOI：

  10.1055/s-0030-1258568
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 amalgamated zinc 作用下， 生成 2-n-Butyl-1-naphthol
  参考文献：
  名称：

  The Fries Reaction with α-Naphthol Esters^1,2

  摘要：

  DOI：

  10.1021/ja01304a056

文献信息

• [EN] SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS<br/>[FR] 1,5-NAPHTYRIDINES OU QUINOLÉINES SUBSTITUÉES EN TANT QU'INHIBITEURS D'ALK5
  申请人：THERAVANCE BIOPHARMA R&D IP LLC

  公开号：WO2021102468A1

  公开（公告）日：2021-05-27

  The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

  本公开提供了激活素受体样激酶5（ALK5）的抑制剂。还公开了调节ALK5活性的方法和通过ALK5介导的疾病的治疗方法。
• [EN] COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR MODULER LA VOIE DE SIGNALISATION WNT
  申请人：IRM LLC

  公开号：WO2012003189A1

  公开（公告）日：2012-01-05

  The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R1, R2, R3 are as defined herein.

  本发明涉及用具有Formula（1）和（3）的化合物调节Wnt信号通路的组合物和方法：其中A、B、Y和Z均代表环，R1、R2、R3如本文所定义。
• STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES
  申请人：STEVENS Christian

  公开号：US20090275616A1

  公开（公告）日：2009-11-05

  The present invention relates to a group of substituted-7-azabicyclo-[2.2.1]heptyl derivatives with biological activity. The present invention also relates to synthetic methods for producing said substituted-7-azabicyclo-[2.2.1]heptyl derivatives. The present invention also relates to certain intermediates for producing such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as a synthetic method for producing such intermediates. The present invention also relates to pharmaceutical compositions comprising such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as their use as medicaments for the treatment of diseases mediated by a Nicotinic Acetylcholine Receptor or a receptor being a member of the Neurotransmitter-gated Ion Channel Superfamily, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and nicotine addiction.

  本发明涉及一组具有生物活性的取代-7-氮杂双环[2.2.1]庚基衍生物。本发明还涉及用于制备所述取代-7-氮杂双环[2.2.1]庚基衍生物的合成方法。本发明还涉及用于制备此类取代-7-氮杂双环[2.2.1]庚基衍生物的某些中间体，以及用于制备此类中间体的合成方法。本发明还涉及包含此类取代-7-氮杂双环[2.2.1]庚基衍生物的药物组合物，以及它们作为治疗由尼古丁乙酰胆碱受体或神经递质门控离子通道超家族成员介导的疾病的药物的用途，如疼痛、阿尔茨海默病、帕金森病、精神分裂症、癫痫和尼古丁成瘾。
• FUSED AMINODIHYDROTHIAZINE DERIVATIVES
  申请人：SUZUKI Yuichi

  公开号：US20090209755A1

  公开（公告）日：2009-08-20

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is —NR e CO— or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一个由以下通用公式表示的化合物：或其药用可接受的盐或其溶剂化物，其中环A是C6-14芳基或类似物，L是—NReCO—或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基烯基或类似物，Y是单键或类似物，Z是C1-3烷基烯基或类似物，R1和R2各自独立地是氢原子或类似物，而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
• [EN] DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS<br/>[FR] COMPOSÉS DÉRIVÉS DE DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2021130259A1

  公开（公告）日：2021-07-01

  The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

  本发明涉及式(I)的二氢环戊基异喹啉磺胺衍生物，以及制备它们的方法、含有它们的药物组合物以及它们在治疗由IgE引起的疾病（如过敏反应、非过敏性肥大细胞反应或某些自身免疫反应）中的用途，特别是由IgE与FcεRI受体相互作用引起的疾病。